Davide Dalu
Overview
Explore the profile of Davide Dalu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leone A, Bonadonna S, Cassani C, Barcellini A, Sirico M, Tagliaferri B, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000330.
PMID: 39886120
Transgender and gender-diverse (TGD) individuals face an elevated risk of cancer in comparison with the general population. This increased risk is primarily attributed to an imbalanced exposure to modifiable risk...
2.
Ruggieri L, Amato O, Marrazzo C, Nebuloni M, Dalu D, Cona M, et al.
Int J Mol Sci
. 2025 Jan;
26(1.
PMID: 39796071
In recent years, awareness regarding micro-nanoplastics' (MNPs) potential effects on human health has progressively increased. Despite a large body of evidence regarding the origin and distribution of MNPs in the...
3.
Dalu D, Ridolfo A, Ruggieri L, Cona M, Riva A, De Francesco D, et al.
Vaccines (Basel)
. 2024 Jun;
12(6).
PMID: 38932371
In patients with cancer, tumor- and treatment-induced immunosuppression are responsible for a four-fold increase in morbidity and mortality caused by influenza and invasive infections compared to the general population. The...
4.
Rizzo A, Dalu D, Moschese D, Giacomelli A
J Med Virol
. 2024 May;
96(5):e29677.
PMID: 38751160
No abstract available.
5.
Giacomelli A, Cattaneo D, Pozza G, Moschese D, Cossu M, Dalu D, et al.
J Antimicrob Chemother
. 2024 Apr;
79(7):1708-1709.
PMID: 38661237
No abstract available.
6.
Rizzo A, Salari F, Eplite A, Giacomelli A, Moschese D, Dalu D, et al.
Infect Dis (Lond)
. 2024 Jan;
56(4):293-298.
PMID: 38217420
Background: Oral human papillomavirus (HPV) is common among healthy individuals but causes and implications of persistent infections are under evaluation in the pathogenesis of head and neck neoplasms. Methods: This...
7.
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study
Pagani C, Rusconi C, Dalla Pria A, Ravano E, Schommers P, Bastos-Oreiro M, et al.
Blood Adv
. 2024 Jan;
8(4):968-977.
PMID: 38207206
Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone...
8.
Dalu D, Tarkowski M, Ruggieri L, Cona M, Gabrieli A, De Francesco D, et al.
Int J Cancer
. 2023 Dec;
154(8):1371-1376.
PMID: 38100252
Solid cancer patients are at higher risk of SARS-CoV-2 infection and severe complications. Moreover, vaccine-induced antibody response is impaired in patients on anticancer treatment. In this retrospective, observational, hypothesis-generating, cohort...
9.
Leone A, Casolino R, Trapani D, Miceli R, Massagrande M, Morano F, et al.
EClinicalMedicine
. 2023 Oct;
65:102277.
PMID: 37877000
Transgender and gender-diverse individuals experience substantial health disparities across the cancer care continuum. Despite well recognized unique healthcare needs, there are barriers in accessing cancer prevention and treatment services, influenced...
10.
Cona M, Riva A, Dalu D, Gabrieli A, Fasola C, Lipari G, et al.
Cancer Med
. 2023 Apr;
12(12):12967-12974.
PMID: 37114577
Introduction: Cancer patients are frail individuals, thus the prevention of SARS-CoV-2 infection is essential. To date, vaccination is the most effective tool to prevent COVID-19. In a previous study, we...